Towards the sustainable discovery and development of new antibiotics.

Ventola, C. L. The antibiotic resistance crisis: part 1: causes and threats. Pharm. Ther. 40, 277–283 (2015). A comprehensive summary of the emergence of antibiotic resistance and the associated clinical and economic burden.

Byrne, M. K. et al. The drivers of antibiotic use and misuse: the development and investigation of a theory driven community measure. BMC Public. Health 19, 1425 (2019).

pubmed: 31666056 pmcid: 6822443 doi: 10.1186/s12889-019-7796-8

Nadimpalli, M. L. et al. Urban informal settlements as hotspots of antimicrobial resistance and the need to curb environmental transmission. Nat. Microbiol. 5, 787–795 (2020).

pubmed: 32467623 doi: 10.1038/s41564-020-0722-0

World Health Organization (WHO). WHO report on surveillance of antibiotic consumption 2016–2018 early implementation (WHO, 2018) https://www.who.int/medicines/areas/rational_use/oms-amr-amc-report-2016-2018/en/

Schrader, S. M., Vaubourgeix, J. & Nathan, C. Biology of antimicrobial resistance and approaches to combat it. Sci. Trans. Med. 12, eaaz6992 (2020).

doi: 10.1126/scitranslmed.aaz6992

Conlon, B. P. et al. Persister formation in Staphylococcus aureus is associated with ATP depletion. Nat. Microbiol. 1, 16051 (2016).

pubmed: 27572649 pmcid: 4932909 doi: 10.1038/nmicrobiol.2016.51

Harms, A., Maisonneuve, E. & Gerdes, K. Mechanisms of bacterial persistence during stress and antibiotic exposure. Science 354, aaf4268 (2016).

pubmed: 27980159 doi: 10.1126/science.aaf4268

Blaskovich, M. A. T. Antibiotics special issue: challenges and opportunities in antibiotic discovery and development. ACS Infect. Dis. 6, 1286–1288 (2020). An excellent special issue combining viewpoints, perspectives, reviews and original research to provide a snapshot of the current state of antibiotic discovery and development.

doi: 10.1021/acsinfecdis.0c00331

O’Neill, J. Tackling drug-resistant infections globally: final report and recommendations. The Review on Antimicrobial Resistance https://amr-review.org/sites/default/files/160518_Final%20paper_with%20cover.pdf (2016). Ground-breaking report and action plan to tackle present and future threats imposed by drug-resistant infections on a global scale.

AMR Industry Alliance. 2020 progress report (AMR Industry Alliance, 2020) https://www.amrindustryalliance.org/wp-content/uploads/2020/01/AMR-2020-Progress-Report.pdf

Zhou, P. et al. Bacterial and fungal infections in COVID-19 patients: A matter of concern. Infect. Control Hospital Epidemiol. 41, 1124–1125 (2020).

doi: 10.1017/ice.2020.156

Chen, X. et al. The microbial coinfection in COVID-19. Appl. Microbiol. Biotechnol. 104, 7777–7785 (2020).

pubmed: 32780290 doi: 10.1007/s00253-020-10814-6 pmcid: 7417782

Zhou, F. et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 395, 1054–1062 (2020).

pubmed: 32171076 pmcid: 7270627 doi: 10.1016/S0140-6736(20)30566-3

Nori, P. et al. Emerging co-pathogens: New Delhi metallo-beta-lactamase producing Enterobacterales infections in New York City COVID-19 patients. Int. J. Antimicrob. Agents 56, 106179 (2020).

pubmed: 32987104 pmcid: 7518801 doi: 10.1016/j.ijantimicag.2020.106179

Getahun, H., Smith, I., Trivedi, K., Paulin, S. & Balkhy, H. H. Tackling antimicrobial resistance in the COVID-19 pandemic. Bull. World Health Organ. 98, 442–442A (2020).

pubmed: 32742026 pmcid: 7375214 doi: 10.2471/BLT.20.268573

Oldenburg, C. E. & Doan, T. Azithromycin for severe COVID-19. Lancet 396, 936–937 (2020).

pubmed: 32896293 pmcid: 7833672 doi: 10.1016/S0140-6736(20)31863-8

Yates, P. A. et al. Doxycycline treatment of high-risk COVID-19-positive patients with comorbid pulmonary disease. Ther. Adv. Respir. Dis. 14, 1753466620951053 (2020).

pubmed: 32873175 pmcid: 7476338 doi: 10.1177/1753466620951053

Sodhi, M. & Etminan, M. Therapeutic potential for tetracyclines in the treatment of COVID-19. Pharmacotherapy 40, 487–488 (2020).

pubmed: 32267566 pmcid: 7262278 doi: 10.1002/phar.2395

Baron, S. A., Devaux, C., Colson, P., Raoult, D. & Rolain, J.-M. Teicoplanin: an alternative drug for the treatment of COVID-19? Int. J. Antimicrob. Agents 55, 105944 (2020).

pubmed: 32179150 pmcid: 7102624 doi: 10.1016/j.ijantimicag.2020.105944

Contou, D. et al. Bacterial and viral co-infections in patients with severe SARS-CoV-2 pneumonia admitted to a French ICU. Ann. Intensive Care 10, 119 (2020).

pubmed: 32894364 pmcid: 7475952 doi: 10.1186/s13613-020-00736-x

Sharifipour, E. et al. Evaluation of bacterial co-infections of the respiratory tract in COVID-19 patients admitted to ICU. BMC Infect. Dis. 20, 646 (2020).

pubmed: 32873235 pmcid: 7461753 doi: 10.1186/s12879-020-05374-z

Langford, B. J. et al. Bacterial co-infection and secondary infection in patients with COVID-19: a living rapid review and meta-analysis. Clin. Microbiol. Infect. 26, 1622–1629 (2020).

pubmed: 32711058 pmcid: 7832079 doi: 10.1016/j.cmi.2020.07.016

Rawson, T. M. et al. Bacterial and fungal co-infection in individuals with coronavirus: A rapid review to support COVID-19 antimicrobial prescribing. Clin. Infect. Dis. 71, 2459–2468 (2020).

pubmed: 32358954

Vaughn, V. M. et al. Empiric antibacterial therapy and community-onset bacterial co-infection in patients hospitalized with COVID-19: a multi-hospital cohort study. Clin. Infect. Dis. 72, e533–e541 (2020).

pmcid: 7499526 doi: 10.1093/cid/ciaa1239

Hsu, J. How covid-19 is accelerating the threat of antimicrobial resistance. BMJ 369, m1983 (2020).

pubmed: 32423901 doi: 10.1136/bmj.m1983

Rawson, T. M., Ming, D., Ahmad, R., Moore, L. S. P. & Holmes, A. H. Antimicrobial use, drug-resistant infections and COVID-19. Nat. Rev. Microbiol. 18, 409–410 (2020).

pubmed: 32488173 doi: 10.1038/s41579-020-0395-y pmcid: 7264971

Bengoechea, J. A. & Bamford, C. G. SARS-CoV-2, bacterial co-infections, and AMR: the deadly trio in COVID-19? EMBO Mol. Med. 12, e12560 (2020).

pubmed: 32453917 pmcid: 7283846 doi: 10.15252/emmm.202012560

Huttner, B. D., Catho, G., Pano-Pardo, J. R., Pulcini, C. & Schouten, J. COVID-19: don’t neglect antimicrobial stewardship principles! Clin. Microbiol. Infect. 26, 808–810 (2020).

pubmed: 32360446 pmcid: 7190532 doi: 10.1016/j.cmi.2020.04.024

Buehrle, D. J. et al. Antibiotic consumption and stewardship at a hospital outside of an early coronavirus disease 2019 epicenter. Antimicrob. Agents Chemother. 64, e01011–e01020 (2020).

pubmed: 32816693 pmcid: 7577150 doi: 10.1128/AAC.01011-20

Nieuwlaat, R. et al. COVID-19 and antimicrobial resistance: parallel and interacting health emergencies. Clin. Infect. Dis. 72, 1657–1659 (2020).

doi: 10.1093/cid/ciaa773

Bassetti, M. & Giacobbe, D. R. A look at the clinical, economic, and societal impact of antimicrobial resistance in 2020. Expert Opin. Pharmacother. 21, 2067–2071 (2020).

pubmed: 32749893 doi: 10.1080/14656566.2020.1802427

Magiorakos, A.-P. et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin. Microbiol. Infect. 18, 268–281 (2012). This article presents the standardized international terminology to describe acquired resistance profiles in bacterial priority pathogens.

pubmed: 21793988 doi: 10.1111/j.1469-0691.2011.03570.x

Xin Yu, J., Hubbard-Lucey, V. M. & Tang, J. Immuno-oncology drug development goes global. Nat. Rev. Drug Discov. 18, 899–900 (2019).

pubmed: 31780841 doi: 10.1038/d41573-019-00167-9

The Pew Charitable Trusts. Tracking the global pipeline of antibiotics in development, April 2020 (The Pew Charitable Trusts, 2020) https://www.pewtrusts.org/en/research-and-analysis/issue-briefs/2020/04/tracking-the-global-pipeline-of-antibiotics-in-development

Beyer, P. & Paulin, S. The antibacterial research and development pipeline needs urgent solutions. ACS Infect. Dis. 6, 1289–1291 (2020).

doi: 10.1021/acsinfecdis.0c00044

World Health Organization (WHO). 2019 Antibacterial agents in clinical development: an analysis of the antibacterial clinical development pipeline. (WHO, 2019) https://apps.who.int/iris/bitstream/handle/10665/330420/9789240000193-eng.pdf

The Pew Charitable Trusts. A scientific roadmap for antibiotic discovery. (The Pew Charitable Trusts, 2016) https://www.pewtrusts.org/en/research-and-analysis/reports/2016/05/a-scientific-roadmap-for-antibiotic-discovery

OECD Publishing. Stemming the superbug tide: Just a few dollars more. (OECD, 2018) https://www.oecd.org/health/stemming-the-superbug-tide-9789264307599-en.htm

Årdal, C. et al. DRIVE-AB report: revitalizing the antibiotic pipeline: Stimulating innovation while driving sustainable use and global access. (DRIVE AB, 2018) http://drive-ab.eu/wp-content/uploads/2018/01/CHHJ5467-Drive-AB-Main-Report-180319-WEB.pdf

Kim, W., Prosen, K. R., Lepore, C. J. & Coukell, A. On the road to discovering urgently needed antibiotics: so close yet so far away. ACS Infect. Dis. 6, 1292–1294 (2020).

pubmed: 32527096 doi: 10.1021/acsinfecdis.0c00100

Theuretzbacher, U., Outterson, K., Engel, A. & Karlén, A. The global preclinical antibacterial pipeline. Nat. Rev. Microbiol. 18, 275–285 (2020). This review summarizes the most recent antibacterial discovery and preclinical development projects in academia and industry on a global scale.

pubmed: 31745331 doi: 10.1038/s41579-019-0288-0

O’Neill, J. Securing new drugs for future generations: the pipeline of antibiotics. (The Review on Antimicrobial Resistance, 2015) https://amr-review.org/sites/default/files/SECURING%20NEW%20DRUGS%20FOR%20FUTURE%20GENERATIONS%20FINAL%20WEB_0.pdf

Hutchings, M. I., Truman, A. W. & Wilkinson, B. Antibiotics: past, present and future. Curr. Opin. Microbiol. 51, 72–80 (2019).

pubmed: 31733401 doi: 10.1016/j.mib.2019.10.008

Lewis, K. The science of antibiotic discovery. Cell 181, 29–45 (2020). Outstanding overview of past achievements as well as current perspectives and challenges in the field of antibiotic discovery.

pubmed: 32197064 doi: 10.1016/j.cell.2020.02.056

Coates, A. R. M., Halls, G. & Hu, Y. Novel classes of antibiotics or more of the same? Br. J. Pharmacol. 163, 184–194 (2011).

pubmed: 21323894 pmcid: 3085877 doi: 10.1111/j.1476-5381.2011.01250.x

Hughes, D. & Karlén, A. Discovery and preclinical development of new antibiotics. Upsala J. Med. Sci. 119, 162–169 (2014).

pubmed: 24646082 pmcid: 4034554 doi: 10.3109/03009734.2014.896437

Jackson, N., Czaplewski, L. & Piddock, L. J. V. Discovery and development of new antibacterial drugs: learning from experience? J. Antimicrob. Chemother. 73, 1452–1459 (2018).

pubmed: 29438542 doi: 10.1093/jac/dky019

Payne, D. J., Gwynn, M. N., Holmes, D. J. & Pompliano, D. L. Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nat. Rev. Drug Discov. 6, 29–40 (2007).

pubmed: 17159923 doi: 10.1038/nrd2201

BEAM Alliance. Supporting financial investments on R&D to de-risk antimicrobial development. (BEAM Alliance, 2019) https://beam-alliance.eu/wp-content/uploads/2019/10/the-beam-push-memo.pdf

Shlaes, D. M. Antibacterial drugs: the last frontier. ACS Infect. Dis. 6, 1313–1314 (2020).

pubmed: 32527094 doi: 10.1021/acsinfecdis.0c00057

Rex, J. H. & Outterson, K. Antibiotic reimbursement in a model delinked from sales: a benchmark-based worldwide approach. Lancet Infect. Dis. 16, 500–505 (2016). This article describes how delinkage models should be built to ensure the development of antibiotics with the greatest possible innovative potential.

pubmed: 27036356 doi: 10.1016/S1473-3099(15)00500-9

Outterson, K. A shot in the arm for new antibiotics. Nat. Biotechnol. 37, 1110–1112 (2019).

pubmed: 31578512 doi: 10.1038/s41587-019-0279-8

Rex, J. H., Fernandez Lynch, H., Cohen, I. G., Darrow, J. J. & Outterson, K. Designing development programs for non-traditional antibacterial agents. Nat. Commun. 10, 3416 (2019). This article discusses strategies focusing on how non-traditional antibacterial products can best be developed.

pubmed: 31366924 pmcid: 6668399 doi: 10.1038/s41467-019-11303-9

Årdal, C. et al. Antibiotic development - economic, regulatory and societal challenges. Nat. Rev. Microbiol. 18, 267–274 (2020).

pubmed: 31745330 doi: 10.1038/s41579-019-0293-3

International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) New AMR Action Fund steps in to save collapsing antibiotic pipeline with pharmaceutical industry investment of US$1 billion. (IFPMA, 2020) https://www.ifpma.org/resource-centre/new-amr-action-fund-steps-in-to-save-collapsing-antibiotic-pipeline/

The Public Health Agency of Sweden. Availability of antibiotics: Reporting of Government Commission. (The Public Health Agency of Sweden, 2017) https://www.folkhalsomyndigheten.se/contentassets/ab79066a80c7477ca5611ccfb211828e/availability-antibiotics-01229-2017-1.pdf

Mullard, A. UK outlines its antibiotic pull incentive plan. Nat. Rev. Drug Discov. 19, 298–299 (2020).

pubmed: 32269311

Mahase, E. UK launches subscription style model for antibiotics to encourage new development. BMJ 369, m2468 (2020).

pubmed: 32554429 doi: 10.1136/bmj.m2468

Bennet, S. M. & Young, S. T. The Pioneering Antimicrobial Subscriptions to End Up Surging Resistance Act of 2020. (The PASTEUR Act. Michael Bennet, U.S. Senator for Colorado); https://www.bennet.senate.gov/public/_cache/files/b/5/b5032465-bf79-4dca-beba-50fb9b0f4aee/C1FD8B8C4143F1332DC6A5E5EC09C83B.bon20468.pdf (2020).

Davis, D. K. Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms Act of 2019. DISARM Act of 2019. (Congress.gov, 2019) https://www.congress.gov/116/bills/hr4100/BILLS-116hr4100ih.pdf (2019).

Balasegaram, M. & Piddock, L. J. V. The Global Antibiotic Research and Development Partnership (GARDP) not-for-profit model of antibiotic development. ACS Infect. Dis. 6, 1295–1298 (2020).

pubmed: 32406675 doi: 10.1021/acsinfecdis.0c00101

Alm, R. A. & Gallant, K. Innovation in antimicrobial resistance: the CARB-X perspective. ACS Infect. Dis. 6, 1317–1322 (2020).

pubmed: 32202756 doi: 10.1021/acsinfecdis.0c00026

Innovative Medicines Initiative (IMI) AMR Accelerator Programme. Collaboration for prevention and treatment of multi-drug resistant bacterial infections (COMBINE, 2019). https://amr-accelerator.eu/project/combine/

BEAM Alliance. BEAM Alliance and global partners call for urgent action on new reimbursement models for life-saving antibiotics. (BEAM Alliance, 2020) https://beam-alliance.eu/wp-content/uploads/2020/09/post-amr-conference-paper.pdf

Engel, A. Fostering antibiotic development through impact funding. ACS Infect. Dis. 6, 1311–1312 (2020).

pubmed: 32527099 doi: 10.1021/acsinfecdis.0c00069

Zuegg, J., Hansford, K. A., Elliott, A. G., Cooper, M. A. & Blaskovich, M. A. T. How to stimulate and facilitate early stage antibiotic discovery. ACS Infect. Dis. 6, 1302–1304 (2020).

pubmed: 32527097 doi: 10.1021/acsinfecdis.0c00163

van Hengel, A. J. & Marin, L. Research, innovation, and policy: an alliance combating antimicrobial resistance. Trends Microbiol. 27, 287–289 (2019).

pubmed: 30638776 doi: 10.1016/j.tim.2018.12.005

Simpkin, V. L., Renwick, M. J., Kelly, R. & Mossialos, E. Incentivising innovation in antibiotic drug discovery and development: progress, challenges and next steps. J. Antibiot. 70, 1087–1096 (2017).

doi: 10.1038/ja.2017.124

BEAM Alliance. Incentivising a sustainable response to the threat of AMR. (BEAM Alliance, 2019) https://beam-alliance.eu/wp-content/uploads/2019/11/the-beam-pull-memo.pdf

European Commission. A European One Health Action Plan against Antimicrobial Resistance. (AMR). (European Commission, 2017) https://ec.europa.eu/health/sites/default/files/antimicrobial_resistance/docs/amr_2017_action-plan.pdf

World Health Organization (WHO). Global action plan on antimicrobial resistance. (WHO, 2015) https://www.who.int/antimicrobial-resistance/publications/global-action-plan/en/

Hughes, J. P., Rees, S., Kalindjian, S. B. & Philpott, K. L. Principles of early drug discovery. Br. J. Pharmacol. 162, 1239–1249 (2011).

pubmed: 21091654 pmcid: 3058157 doi: 10.1111/j.1476-5381.2010.01127.x

Reddy, A. S. & Zhang, S. Polypharmacology: drug discovery for the future. Expert Rev. Clin. Pharmacol. 6, 41–47 (2013). This review outlines the latest progress and challenges in polypharmacology studies.

pubmed: 23272792 doi: 10.1586/ecp.12.74

Tyers, M. & Wright, G. D. Drug combinations: a strategy to extend the life of antibiotics in the 21st century. Nat. Rev. Microbiol. 17, 141–155 (2019).

pubmed: 30683887 doi: 10.1038/s41579-018-0141-x

O’Shea, R. & Moser, H. E. Physicochemical properties of antibacterial compounds: implications for drug discovery. J. Med. Chem. 51, 2871–2878 (2008).

pubmed: 18260614 doi: 10.1021/jm700967e

Reck, F., Jansen, J. M. & Moser, H. E. Challenges of antibacterial drug discovery. Arkivoc 2019, 227–244 (2020). This study highlights challenges in the discovery of antibiotics, with a focus on physicochemical parameters and preferred property space.

doi: 10.24820/ark.5550190.p010.955

AMR Industry Alliance. Declaration by the pharmaceutical, biotechnology and diagnostics industries on combating antimicrobial resistance. (AMR Industry Alliance, 2016) https://www.amrindustryalliance.org/wp-content/uploads/2017/12/AMR-Industry-Declaration.pdf

Karawajczyk, A., Orrling, K. M., Vlieger, J. S. B., de, Rijnders, T. & Tzalis, D. The European lead factory: a blueprint for public-private partnerships in early drug discovery. Front. Med. 3, 75 (2016).

Morgentin, R. et al. Translation of innovative chemistry into screening libraries: an exemplar partnership from the European Lead Factory. Drug Discov. Today 23, 1578–1583 (2018).

pubmed: 29753124 doi: 10.1016/j.drudis.2018.05.007

Besnard, J., Jones, P. S., Hopkins, A. L. & Pannifer, A. D. The Joint European Compound Library: boosting precompetitive research. Drug Discov. Today 20, 181–186 (2015).

pubmed: 25205347 doi: 10.1016/j.drudis.2014.08.014

Theuretzbacher, U. & Piddock, L. J. V. Non-traditional antibacterial therapeutic options and challenges. Cell Host Microbe 26, 61–72 (2019). Comprehensive overview of non-traditional approaches in antibacterial therapy.

pubmed: 31295426 doi: 10.1016/j.chom.2019.06.004

Fleitas Martínez, O., Cardoso, M. H., Ribeiro, S. M. & Franco, O. L. Recent advances in anti-virulence therapeutic strategies with a focus on dismantling bacterial membrane microdomains, toxin neutralization, quorum-sensing interference and biofilm inhibition. Front. Cell. Infect. Microbiol. 9, 74 (2019).

pubmed: 31001485 pmcid: 6454102 doi: 10.3389/fcimb.2019.00074

Kumar, A., Ellermann, M. & Sperandio, V. Taming the beast: Interplay between gut small molecules and enteric pathogens. Infect. Immun. 87, e00131-19 (2019).

pubmed: 31262983 pmcid: 6704596 doi: 10.1128/IAI.00131-19

Laws, M., Shaaban, A. & Rahman, K. M. Antibiotic resistance breakers: current approaches and future directions. FEMS Microbiol. Rev. 43, 490–516 (2019).

pubmed: 31150547 pmcid: 6736374 doi: 10.1093/femsre/fuz014

Annunziato, G. Strategies to overcome antimicrobial resistance (AMR) making use of non-essential target inhibitors: a review. Int. J. Mol. Sci. 20, 5844 (2019).

pmcid: 6928725 doi: 10.3390/ijms20235844

Calvert, M. B., Jumde, V. R. & Titz, A. Pathoblockers or antivirulence drugs as a new option for the treatment of bacterial infections. Beilstein J. Org. Chem. 14, 2607–2617 (2018).

pubmed: 30410623 pmcid: 6204809 doi: 10.3762/bjoc.14.239

Schütz, C. & Empting, M. Targeting the Pseudomonas quinolone signal quorum sensing system for the discovery of novel anti-infective pathoblockers. Beilstein J. Org. Chem. 14, 2627–2645 (2018).

pubmed: 30410625 pmcid: 6204780 doi: 10.3762/bjoc.14.241

Sommer, R. et al. Glycomimetic, orally bioavailable LecB inhibitors block biofilm formation of pseudomonas aeruginosa. J. Am. Chem. Soc. 140, 2537–2545 (2018). Example of synthetic pathoblockers acting against biofilm formation of Pseudomonas aeruginosa.

pubmed: 29272578 doi: 10.1021/jacs.7b11133

Boudaher, E. & Shaffer, C. L. Inhibiting bacterial secretion systems in the fight against antibiotic resistance. MedChemComm 10, 682–692 (2019).

pubmed: 31741728 pmcid: 6677025 doi: 10.1039/C9MD00076C

Duncan, M. C., Linington, R. G. & Auerbuch, V. Chemical inhibitors of the type three secretion system: disarming bacterial pathogens. Antimicrob. Agents Chemother. 56, 5433–5441 (2012).

pubmed: 22850518 pmcid: 3486574 doi: 10.1128/AAC.00975-12

Schönauer, E. et al. Discovery of a potent inhibitor class with high selectivity toward clostridial collagenases. J. Am. Chem. Soc. 139, 12696–12703 (2017).

pubmed: 28820255 pmcid: 5607459 doi: 10.1021/jacs.7b06935

Paolino, M. et al. Development of potent inhibitors of the Mycobacterium tuberculosis virulence factor Zmp1 and evaluation of their effect on mycobacterial survival inside macrophages. ChemMedChem 13, 422–430 (2018).

pubmed: 29334428 doi: 10.1002/cmdc.201700759

Marshall, R. L. et al. New multidrug efflux inhibitors for Gram-negative bacteria. mBio 11, e01340-20 (2020).

pubmed: 32665275 pmcid: 7360932 doi: 10.1128/mBio.01340-20

Bush, K. & Bradford, P. A. Interplay between β-lactamases and new β-lactamase inhibitors. Nat. Rev. Microbiol. 17, 295–306 (2019).

doi: 10.1038/s41579-019-0159-8 pubmed: 30837684

Tooke, C. L. et al. β-Lactamases and β-lactamase inhibitors in the 21st century. J. Mol. Biol. 431, 3472–3500 (2019).

pubmed: 30959050 pmcid: 6723624 doi: 10.1016/j.jmb.2019.04.002

Smirnova, G. V. & Oktyabrsky, O. N. Glutathione in bacteria. Biochemistry 70, 1199–1211 (2005).

pubmed: 16336178

Chen, N. H. et al. A glutathione-dependent detoxification system is required for formaldehyde resistance and optimal survival of Neisseria meningitidis in biofilms. Antioxid. Redox Signal. 18, 743–755 (2013).

pubmed: 22937752 pmcid: 3555115 doi: 10.1089/ars.2012.4749

Lu, P. et al. The anti-mycobacterial activity of the cytochrome bcc inhibitor Q203 can be enhanced by small-molecule inhibition of cytochrome bd. Sci. Rep. 8, 2625 (2018).

pubmed: 29422632 pmcid: 5805707 doi: 10.1038/s41598-018-20989-8

Iqbal, I. K., Bajeli, S., Akela, A. K. & Kumar, A. Bioenergetics of Mycobacterium: an emerging landscape for drug discovery. Pathogens 7, 24 (2018).

pmcid: 5874750 doi: 10.3390/pathogens7010024

Fol, M., Włodarczyk, M. & Druszczyn´ska, M. Host epigenetics in intracellular pathogen infections. Int. J. Mol. Sci. 21, 4573 (2020).

pmcid: 7369821 doi: 10.3390/ijms21134573

Ghosh, D., Veeraraghavan, B., Elangovan, R. & Vivekanandan, P. Antibiotic resistance and epigenetics: more to it than meets the eye. Antimicrob. Agents Chemother. 64, e02225-19 (2020).

pubmed: 31740560 pmcid: 6985748 doi: 10.1128/AAC.02225-19

Venter, H. Reversing resistance to counter antimicrobial resistance in the World Health Organisation’s critical priority of most dangerous pathogens. Biosci. Rep. 39, BSR20180474 (2019).

pubmed: 30910848 pmcid: 6465202 doi: 10.1042/BSR20180474

Rezzoagli, C., Archetti, M., Mignot, I., Baumgartner, M. & Kümmerli, R. Combining antibiotics with antivirulence compounds can have synergistic effects and reverse selection for antibiotic resistance in Pseudomonas aeruginosa. PLoS Biol. 18, e3000805 (2020).

pubmed: 32810152 pmcid: 7433856 doi: 10.1371/journal.pbio.3000805

Strich, J. R. et al. Needs assessment for novel Gram-negative antibiotics in US hospitals: a retrospective cohort study. Lancet Infect. Dis. 20, 1172–1181 (2020).

pubmed: 32505231 pmcid: 7272178 doi: 10.1016/S1473-3099(20)30153-5

Lakemeyer, M., Zhao, W., Mandl, F. A., Hammann, P. & Sieber, S. A. Thinking outside the box — novel antibacterials to tackle the resistance crisis. Angew. Chem. Int. Ed. 57, 14440–14475 (2018). Extensive and interdisciplinary overview of methods for mining novel antibiotics and strategies to unravel their modes of action.

doi: 10.1002/anie.201804971

Hennessen, F. et al. Amidochelocardin overcomes resistance mechanisms exerted on tetracyclines and natural chelocardin. Antibiotics 9, 619 (2020).

pmcid: 7559539 doi: 10.3390/antibiotics9090619

Sarigul, N., Korkmaz, F. & Kurultak, I∙. A new artificial urine protocol to better imitate human urine. Sci. Rep. 9, 20159 (2019).

pubmed: 31882896 pmcid: 6934465 doi: 10.1038/s41598-019-56693-4

Ganz, T. & Nemeth, E. Iron homeostasis in host defence and inflammation. Nat. Rev. Immunol. 15, 500–510 (2015).

pubmed: 26160612 pmcid: 4801113 doi: 10.1038/nri3863

Martins, A. C., Almeida, J. I., Lima, I. S., Kapitão, A. S. & Gozzelino, R. Iron metabolism and the inflammatory response. IUBMB Life 69, 442–450 (2017).

pubmed: 28474474 doi: 10.1002/iub.1635

Krismer, B., Weidenmaier, C., Zipperer, A. & Peschel, A. The commensal lifestyle of Staphylococcus aureus and its interactions with the nasal microbiota. Nat. Rev. Microbiol. 15, 675–687 (2017).

pubmed: 29021598 doi: 10.1038/nrmicro.2017.104

Ayaz, M. et al. Synergistic interactions of phytochemicals with antimicrobial agents: Potential strategy to counteract drug resistance. Chem. Biol. Interact. 308, 294–303 (2019).

pubmed: 31158333 doi: 10.1016/j.cbi.2019.05.050

Mahomoodally, M. F. & Sadeer, N. B. Antibiotic potentiation of natural products: A promising target to fight pathogenic bacteria. Curr. Drug Targets 22, 555–572 (2020).

Parkinson, E. I. et al. Deoxynybomycins inhibit mutant DNA gyrase and rescue mice infected with fluoroquinolone-resistant bacteria. Nat. Commun. 6, 6947 (2015).

pubmed: 25907309 doi: 10.1038/ncomms7947

King, A. M. et al. Aspergillomarasmine A overcomes metallo-β-lactamase antibiotic resistance. Nature 510, 503–506 (2014).

pubmed: 24965651 pmcid: 4981499 doi: 10.1038/nature13445

Park, S. W. et al. Target-based identification of whole-cell active inhibitors of biotin biosynthesis in Mycobacterium tuberculosis. Chem. Biol. 22, 76–86 (2015).

pubmed: 25556942 doi: 10.1016/j.chembiol.2014.11.012

Verma, S. & Prabhakar, Y. S. Target based drug design - a reality in virtual sphere. Curr. Med. Chem. 22, 1603–1630 (2015).

pubmed: 25666805 doi: 10.2174/0929867322666150209151209

Graef, F. et al. In vitro model of the Gram-negative bacterial cell envelope for investigation of anti-infective permeation kinetics. ACS Infect. Dis. 4, 1188–1196 (2018).

pubmed: 29750862 doi: 10.1021/acsinfecdis.7b00165

Richter, R. et al. A hydrogel-based in vitro assay for the fast prediction of antibiotic accumulation in Gram-negative bacteria. Mater. Today Bio 8, 100084 (2020).

pubmed: 33313504 pmcid: 7720078 doi: 10.1016/j.mtbio.2020.100084

Martin, E. J. et al. All-Assay-Max2 pQSAR: activity predictions as accurate as four-concentration IC

pubmed: 31518124 doi: 10.1021/acs.jcim.9b00375

Durrant, J. D. & Amaro, R. E. Machine-learning techniques applied to antibacterial drug discovery. Chem. Biol. Drug Des. 85, 14–21 (2015).

pubmed: 25521642 pmcid: 4273861 doi: 10.1111/cbdd.12423

Newman, D. J. & Cragg, G. M. Natural products as sources of new drugs over the nearly four decades from 01/1981 to 09/2019. J. Nat. Prod. 83, 770–803 (2020). Fundamental review addressing the role of natural products in drug discovery during the past 40 years.

pubmed: 32162523 doi: 10.1021/acs.jnatprod.9b01285

Locey, K. J. & Lennon, J. T. Scaling laws predict global microbial diversity. Proc. Natl Acad. Sci. USA 113, 5970–5975 (2016).

pubmed: 27140646 pmcid: 4889364 doi: 10.1073/pnas.1521291113

Thompson, L. R. et al. A communal catalogue reveals Earth’s multiscale microbial diversity. Nature 551, 457–463 (2017).

pubmed: 29088705 pmcid: 6192678 doi: 10.1038/nature24621

Mousa, W. K., Athar, B., Merwin, N. J. & Magarvey, N. A. Antibiotics and specialized metabolites from the human microbiota. Nat. Prod. Rep. 34, 1302–1331 (2017).

pubmed: 29018846 doi: 10.1039/C7NP00021A

Zipperer, A. et al. Human commensals producing a novel antibiotic impair pathogen colonization. Nature 535, 511–516 (2016). Research article describing the discovery of the novel antibiotic lugdunin produced by commensals of the human nasal microbiome.

pubmed: 27466123 doi: 10.1038/nature18634

Imai, Y. et al. A new antibiotic selectively kills Gram-negative pathogens. Nature 576, 459–464 (2019). This study describes the discovery of the new antibiotic darobactin that is active against Gram-negative pathogens.

pubmed: 31747680 pmcid: 7188312 doi: 10.1038/s41586-019-1791-1

Adnani, N., Rajski, S. R. & Bugni, T. S. Symbiosis-inspired approaches to antibiotic discovery. Nat. Prod. Rep. 34, 784–814 (2017).

pubmed: 28561849 pmcid: 5555300 doi: 10.1039/C7NP00009J

Lodhi, A. F., Zhang, Y., Adil, M. & Deng, Y. Antibiotic discovery: combining isolation chip (iChip) technology and co-culture technique. Appl. Microbiol. Biotechnol. 102, 7333–7341 (2018).

pubmed: 29974183 doi: 10.1007/s00253-018-9193-0

Kealey, C., Creaven, C. A., Murphy, C. D. & Brady, C. B. New approaches to antibiotic discovery. Biotechnol. Lett. 39, 805–817 (2017).

pubmed: 28275884 doi: 10.1007/s10529-017-2311-8

Ling, L. L. et al. A new antibiotic kills pathogens without detectable resistance. Nature 517, 455–459 (2015). An intriguing example of discovering a new antibiotic (teixobactin) from uncultured bacteria by using innovative cultivation techniques (iChip).

pubmed: 25561178 pmcid: 7414797 doi: 10.1038/nature14098

Ma, L. et al. Gene-targeted microfluidic cultivation validated by isolation of a gut bacterium listed in Human Microbiome Project’s Most Wanted taxa. Proc. Natl Acad. Sci. USA 111, 9768–9773 (2014).

pubmed: 24965364 pmcid: 4103313 doi: 10.1073/pnas.1404753111

Mahler, L. et al. Highly parallelized microfluidic droplet cultivation and prioritization on antibiotic producers from complex natural microbial communities. eLife 10, e64774 (2021).

pubmed: 33764297 pmcid: 8081529 doi: 10.7554/eLife.64774

Jiang, C.-Y. et al. High-throughput single-cell cultivation on microfluidic streak plates. Appl. Environ. Microbiol. 82, 2210–2218 (2016).

pubmed: 26850294 pmcid: 4807504 doi: 10.1128/AEM.03588-15

Seyedsayamdost, M. R. High-throughput platform for the discovery of elicitors of silent bacterial gene clusters. Proc. Natl Acad. Sci. USA 111, 7266–7271 (2014).

pubmed: 24808135 pmcid: 4034229 doi: 10.1073/pnas.1400019111

Pishchany, G. et al. Amycomicin is a potent and specific antibiotic discovered with a targeted interaction screen. Proc. Natl Acad. Sci. USA 115, 10124–10129 (2018).

pubmed: 30228116 pmcid: 6176635 doi: 10.1073/pnas.1807613115

Chaudhary, D. K., Khulan, A. & Kim, J. Development of a novel cultivation technique for uncultured soil bacteria. Sci. Rep. 9, 6666 (2019).

pubmed: 31040339 pmcid: 6491550 doi: 10.1038/s41598-019-43182-x

Masschelein, J., Jenner, M. & Challis, G. L. Antibiotics from Gram-negative bacteria: a comprehensive overview and selected biosynthetic highlights. Nat. Prod. Rep. 34, 712–783 (2017).

pubmed: 28650032 doi: 10.1039/C7NP00010C

Hoffmann, T. et al. Correlating chemical diversity with taxonomic distance for discovery of natural products in myxobacteria. Nat. Commun. 9, 803 (2018). This study underpins the ‘taxonomy paradigm’, suggesting to explore new genera of microorganisms to increase the chance of finding novel antibiotic chemotypes.

pubmed: 29476047 pmcid: 5824889 doi: 10.1038/s41467-018-03184-1

Hughes, C. C. & Fenical, W. Antibacterials from the sea. Chem. Eur. J. 16, 12512–12525 (2010).

pubmed: 20845412 doi: 10.1002/chem.201001279

Abrudan, M. I. et al. Socially mediated induction and suppression of antibiosis during bacterial coexistence. Proc. Natl Acad. Sci. USA 112, 11054–11059 (2015).

pubmed: 26216986 pmcid: 4568218 doi: 10.1073/pnas.1504076112

Granato, E. T., Meiller-Legrand, T. A. & Foster, K. R. The evolution and ecology of bacterial warfare. Curr. Biol. 29, R521–R537 (2019).

pubmed: 31163166 doi: 10.1016/j.cub.2019.04.024

Kraemer, S. A., Ramachandran, A. & Perron, G. G. Antibiotic pollution in the environment: from microbial ecology to public policy. Microorganisms 7, 180 (2019).

pmcid: 6616856 doi: 10.3390/microorganisms7060180

Ju, F. et al. Wastewater treatment plant resistomes are shaped by bacterial composition, genetic exchange, and upregulated expression in the effluent microbiomes. ISME J. 13, 346–360 (2019).

pubmed: 30250051 doi: 10.1038/s41396-018-0277-8

Sierra-Zapata, L. et al. Inducible antibacterial activity in the bacillales by triphenyl tetrazolium chloride. Sci. Rep. 10, 5563 (2020).

pubmed: 32221330 pmcid: 7101371 doi: 10.1038/s41598-020-62236-z

Charusanti, P. et al. Exploiting adaptive laboratory evolution of Streptomyces clavuligerus for antibiotic discovery and overproduction. PLoS One 7, e33727 (2012).

pubmed: 22470465 pmcid: 3312335 doi: 10.1371/journal.pone.0033727

Cowan, M. M. Plant products as antimicrobial agents. Clin. Microbiol. Rev. 12, 564–582 (1999).

pubmed: 10515903 pmcid: 88925 doi: 10.1128/CMR.12.4.564

Newman, D. J. & Cragg, G. M. Plant endophytes and epiphytes: Burgeoning sources of known and “unknown” cytotoxic and antibiotic agents? Planta Medica 86, 891–905 (2020).

pubmed: 32023633 doi: 10.1055/a-1095-1111

Hyde, K. D. et al. The amazing potential of fungi: 50 ways we can exploit fungi industrially. Fungal Divers. 97, 1–136 (2019).

doi: 10.1007/s13225-019-00430-9

Silva, O. N. et al. Repurposing a peptide toxin from wasp venom into antiinfectives with dual antimicrobial and immunomodulatory properties. Proc. Natl Acad. Sci. USA 117, 26936–26945 (2020).

pubmed: 33046640 pmcid: 7604428 doi: 10.1073/pnas.2012379117

Medema, M. H. & Fischbach, M. A. Computational approaches to natural product discovery. Nat. Chem. Biol. 11, 639–648 (2015).

pubmed: 26284671 pmcid: 5024737 doi: 10.1038/nchembio.1884

Katz, M., Hover, B. M. & Brady, S. F. Culture-independent discovery of natural products from soil metagenomes. J. Ind. Microbiol. Biotechnol. 43, 129–141 (2016).

pubmed: 26586404 doi: 10.1007/s10295-015-1706-6

Crits-Christoph, A., Diamond, S., Butterfield, C. N., Thomas, B. C. & Banfield, J. F. Novel soil bacteria possess diverse genes for secondary metabolite biosynthesis. Nature 558, 440–444 (2018).

pubmed: 29899444 doi: 10.1038/s41586-018-0207-y

Milshteyn, A., Schneider, J. S. & Brady, S. F. Mining the metabiome: identifying novel natural products from microbial communities. Chem. Biol. 21, 1211–1223 (2014).

pubmed: 25237864 pmcid: 4171686 doi: 10.1016/j.chembiol.2014.08.006

Myronovskyi, M. et al. Generation of a cluster-free Streptomyces albus chassis strains for improved heterologous expression of secondary metabolite clusters. Metab. Eng. 49, 316–324 (2018).

pubmed: 30196100 doi: 10.1016/j.ymben.2018.09.004

Gomez-Escribano, J. P. & Bibb, M. J. Engineering Streptomyces coelicolor for heterologous expression of secondary metabolite gene clusters. Microb. Biotechnol. 4, 207–215 (2011).

pubmed: 21342466 pmcid: 3818861 doi: 10.1111/j.1751-7915.2010.00219.x

Komatsu, M. et al. Engineered Streptomyces avermitilis host for heterologous expression of biosynthetic gene cluster for secondary metabolites. ACS Synth. Biol. 2, 384–396 (2013).

pubmed: 23654282 pmcid: 3932656 doi: 10.1021/sb3001003

Sherwood, E. J., Hesketh, A. R. & Bibb, M. J. Cloning and analysis of the planosporicin lantibiotic biosynthetic gene cluster of Planomonospora alba. J. Bacteriol. 195, 2309–2321 (2013).

pubmed: 23475977 pmcid: 3650528 doi: 10.1128/JB.02291-12

Ahmed, Y. et al. Engineering of Streptomyces lividans for heterologous expression of secondary metabolite gene clusters. Microb. Cell Fact. 19, 5 (2020).

pubmed: 31918711 pmcid: 6950998 doi: 10.1186/s12934-020-1277-8

Wang, G. et al. CRAGE enables rapid activation of biosynthetic gene clusters in undomesticated bacteria. Nat. Microbiol. 4, 2498–2510 (2019).

pubmed: 31611640 doi: 10.1038/s41564-019-0573-8

Tong, Y., Weber, T. & Lee, S. Y. CRISPR/Cas-based genome engineering in natural product discovery. Nat. Prod. Rep. 36, 1262–1280 (2019). This review summarizes the current knowledge about the CRISPR/Cas system and how it became one of the most important tools for genome editing.

pubmed: 30548045 doi: 10.1039/C8NP00089A

La Fuente-Núñez, C. de & Lu, T. K. CRISPR-Cas9 technology: applications in genome engineering, development of sequence-specific antimicrobials, and future prospects. Integr. Biol. 9, 109–122 (2017).

doi: 10.1039/c6ib00140h

Wang, H. et al. ExoCET: exonuclease in vitro assembly combined with RecET recombination for highly efficient direct DNA cloning from complex genomes. Nucleic Acids Res. 46, e28 (2018).

pubmed: 29240926 doi: 10.1093/nar/gkx1249

Zeng, F. et al. AFEAP cloning: a precise and efficient method for large DNA sequence assembly. BMC Biotechnol. 17, 81 (2017).

pubmed: 29137618 pmcid: 5686892 doi: 10.1186/s12896-017-0394-x

Snoeck, N. et al. Serine integrase recombinational engineering (SIRE): A versatile toolbox for genome editing. Biotechnol. Bioeng. 116, 364–374 (2019).

pubmed: 30345503 doi: 10.1002/bit.26854

Kautsar, S. A. et al. MIBiG 2.0: a repository for biosynthetic gene clusters of known function. Nucleic Acids Res. 48, D454–D458 (2020). This article presents a major update of the ‘Minimum Information about a Biosynthetic Gene cluster’ (MIBiG) data repository.

pubmed: 31612915

Blin, K. et al. antiSMASH 5.0: updates to the secondary metabolite genome mining pipeline. Nucleic Acids Res. 47, W81–W87 (2019). This article presents an entirely redesigned and extended version of the ‘antibiotics and secondary metabolite analysis shell’: antiSMASH.

pubmed: 31032519 pmcid: 6602434 doi: 10.1093/nar/gkz310

Skinnider, M. A. et al. Comprehensive prediction of secondary metabolite structure and biological activity from microbial genome sequences. Nat. Commun. 11, 6058 (2020).

pubmed: 33247171 pmcid: 7699628 doi: 10.1038/s41467-020-19986-1

Alanjary, M., Cano-Prieto, C., Gross, H. & Medema, M. H. Computer-aided re-engineering of nonribosomal peptide and polyketide biosynthetic assembly lines. Nat. Prod. Rep. 36, 1249–1261 (2019).

pubmed: 31259995 doi: 10.1039/C9NP00021F

Cummings, M. et al. Assembling a plug-and-play production line for combinatorial biosynthesis of aromatic polyketides in Escherichia coli. PLoS Biol. 17, e3000347 (2019).

pubmed: 31318855 pmcid: 6638757 doi: 10.1371/journal.pbio.3000347

Hwang, S., Lee, N., Cho, S., Palsson, B. & Cho, B.-K. Repurposing modular polyketide synthases and non-ribosomal peptide synthetases for novel chemical biosynthesis. Front. Mol. Biosci. 7, 87 (2020).

pubmed: 32500080 pmcid: 7242659 doi: 10.3389/fmolb.2020.00087

Bozhüyük, K. A. J. et al. Modification and de novo design of non-ribosomal peptide synthetases using specific assembly points within condensation domains. Nat. Chem. 11, 653–661 (2019).

pubmed: 31182822 doi: 10.1038/s41557-019-0276-z

Luo, Y., Enghiad, B. & Zhao, H. New tools for reconstruction and heterologous expression of natural product biosynthetic gene clusters. Nat. Prod. Rep. 33, 174–182 (2016).

pubmed: 26647833 pmcid: 4742407 doi: 10.1039/C5NP00085H

Tan, G.-Y. & Liu, T. Rational synthetic pathway refactoring of natural products biosynthesis in actinobacteria. Metab. Eng. 39, 228–236 (2017).

pubmed: 28013086 doi: 10.1016/j.ymben.2016.12.006

Zhang, J. J., Tang, X. & Moore, B. S. Genetic platforms for heterologous expression of microbial natural products. Nat. Prod. Rep. 36, 1313–1332 (2019). This review highlights the present arsenal of genetic platforms to identify, evaluate and engineer biosynthetic gene clusters from diverse microbial sources.

pubmed: 31197291 pmcid: 6750982 doi: 10.1039/C9NP00025A

Huo, L. et al. Heterologous expression of bacterial natural product biosynthetic pathways. Nat. Prod. Rep. 36, 1412–1436 (2019).

pubmed: 30620035 doi: 10.1039/C8NP00091C

Ito, T. & Masubuchi, M. Dereplication of microbial extracts and related analytical technologies. J. Antibiot. 67, 353–360 (2014).

doi: 10.1038/ja.2014.12

Quinn, R. A. et al. Molecular networking as a drug discovery, drug metabolism, and precision medicine strategy. Trends Pharmacol. Sci. 38, 143–154 (2017).

pubmed: 27842887 doi: 10.1016/j.tips.2016.10.011

Ernst, M. et al. MolNetEnhancer: Enhanced molecular networks by integrating metabolome mining and annotation tools. Metabolites 9, 144 (2019).

pmcid: 6680503 doi: 10.3390/metabo9070144

Liebal, U. W., Phan, A. N. T., Sudhakar, M., Raman, K. & Blank, L. M. Machine learning applications for mass spectrometry-based metabolomics. Metabolites 10, 243 (2020).

pmcid: 7345470 doi: 10.3390/metabo10060243

Hubert, J., Nuzillard, J.-M. & Renault, J.-H. Dereplication strategies in natural product research: How many tools and methodologies behind the same concept? Phytochem. Rev. 16, 55–95 (2017).

doi: 10.1007/s11101-015-9448-7

Li, Y., Kuhn, M., Gavin, A.-C. & Bork, P. Identification of metabolites from tandem mass spectra with a machine learning approach utilizing structural features. Bioinformatics 36, 1213–1218 (2020).

pubmed: 31605112 doi: 10.1093/bioinformatics/btz736

Zani, C. L. & Carroll, A. R. Database for rapid dereplication of known natural products using data from MS and Fast NMR experiments. J. Nat. Prod. 80, 1758–1766 (2017).

pubmed: 28616931 doi: 10.1021/acs.jnatprod.6b01093

van Santen, J. A. et al. The natural products atlas: an open access knowledge base for microbial natural products discovery. ACS Cent. Sci. 5, 1824–1833 (2019).

pubmed: 31807684 pmcid: 6891855 doi: 10.1021/acscentsci.9b00806

Wang, M. et al. Sharing and community curation of mass spectrometry data with global natural products social molecular networking. Nat. Biotechnol. 34, 828–837 (2016).

pubmed: 27504778 pmcid: 5321674 doi: 10.1038/nbt.3597

Guijas, C. et al. METLIN: a technology platform for identifying knowns and unknowns. Anal. Chem. 90, 3156–3164 (2018).

pubmed: 29381867 pmcid: 5933435 doi: 10.1021/acs.analchem.7b04424

Kuhn, S. & Schlörer, N. E. Facilitating quality control for spectra assignments of small organic molecules: nmrshiftdb2–a free in-house NMR database with integrated LIMS for academic service laboratories. Magn. Reson. Chem. 53, 582–589 (2015).

pubmed: 25998807 doi: 10.1002/mrc.4263

López-Pérez, J. L., Therón, R., del Olmo, E. & Díaz, D. NAPROC-13: a database for the dereplication of natural product mixtures in bioassay-guided protocols. Bioinformatics 23, 3256–3257 (2007).

pubmed: 17956876 doi: 10.1093/bioinformatics/btm516

Bader, C. D., Neuber, M., Panter, F., Krug, D. & Müller, R. Supercritical fluid extraction enhances discovery of secondary metabolites from myxobacteria. Anal. Chem. 92, 15403–15411 (2020).

pubmed: 33171050 doi: 10.1021/acs.analchem.0c02995

Nass, N. M. et al. Revisiting unexploited antibiotics in search of new antibacterial drug candidates: the case of γ-actinorhodin. Sci. Rep. 7, 17419 (2017).

pubmed: 29234001 pmcid: 5727142 doi: 10.1038/s41598-017-17232-1

Ishikawa, M. et al. Lower ototoxicity and absence of hidden hearing loss point to gentamicin C1a and apramycin as promising antibiotics for clinical use. Sci. Rep. 9, 2410 (2019).

pubmed: 30787404 pmcid: 6382871 doi: 10.1038/s41598-019-38634-3

Lešnik, U. et al. Construction of a new class of tetracycline lead structures with potent antibacterial activity through biosynthetic engineering. Angew. Chem. Int. Ed. 54, 3937–3940 (2015).

doi: 10.1002/anie.201411028

Grandclaudon, C. et al. Semisynthesis and biological evaluation of amidochelocardin derivatives as broad-spectrum antibiotics. Eur. J. Med. Chem. 188, 112005 (2020).

pubmed: 31911294 doi: 10.1016/j.ejmech.2019.112005

Omollo, C. et al. Developing synergistic drug combinations to restore antibiotic sensitivity in drug-resistant Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 65, e02554-20 (2021).

doi: 10.1128/AAC.02554-20 pmcid: 8092878

Tan, J. H. et al. In vitro and in vivo efficacy of an LpxC inhibitor, CHIR-090, alone or combined with colistin against Pseudomonas aeruginosa biofilm. Antimicrob. Agents Chemother. 61, e02223-16 (2017).

pubmed: 28461320 pmcid: 5487635 doi: 10.1128/AAC.02223-16

Mariathasan, S. & Tan, M.-W. Antibody–antibiotic conjugates: a novel therapeutic platform against bacterial infections. Trends Mol. Med. 23, 135–149 (2017).

pubmed: 28126271 doi: 10.1016/j.molmed.2016.12.008

Koenig, S. G. & Pillow, T. H. in Complete Accounts of Integrated Drug Discovery and Development: Recent Examples from the Pharmaceutical Industry Volume 2 Vol. 1332 (eds Pesti, J. A., Abdel-Magid, A. F. & Vaidyanathan, R.) 85–105 (American Chemical Society, 2019).

Negash, K. H., Norris, J. K. S. & Hodgkinson, J. T. Siderophore–antibiotic conjugate design: New drugs for bad bugs? Molecules 24, 3314 (2019).

pmcid: 6767078 doi: 10.3390/molecules24183314

Schalk, I. J. Siderophore–antibiotic conjugates: exploiting iron uptake to deliver drugs into bacteria. Clin. Microbiol. Infect. 24, 801–802 (2018).

pubmed: 29649600 doi: 10.1016/j.cmi.2018.03.037

Blaskovich, M. A. T. et al. Protein-inspired antibiotics active against vancomycin- and daptomycin-resistant bacteria. Nat. Commun. 9, 22 (2018). This study shows how positively charged effector sequences can ‘revitalize’ antibiotics that have lost effectiveness against recalcitrant bacteria.

pubmed: 29295973 pmcid: 5750218 doi: 10.1038/s41467-017-02123-w

Umstätter, F. et al. Vancomycin resistance is overcome by conjugation of polycationic peptides. Angew. Chem. Int. Ed. 59, 8823–8827 (2020).

doi: 10.1002/anie.202002727

Kim, A. et al. Pharmacodynamic profiling of a siderophore-conjugated monocarbam in Pseudomonas aeruginosa: assessing the risk for resistance and attenuated efficacy. Antimicrob. Agents Chemother. 59, 7743–7752 (2015).

pubmed: 26438502 pmcid: 4649189 doi: 10.1128/AAC.00831-15

Stokes, J. M. et al. A deep learning approach to antibiotic discovery. Cell 180, 688–702.e13 (2020). This work demonstrates how deep learning approaches can expand the antibiotic arsenal through the discovery of structurally distinct hit compounds.

pubmed: 32084340 pmcid: 8349178 doi: 10.1016/j.cell.2020.01.021

de la Fuente-Nunez, C. Toward autonomous antibiotic discovery. mSystems 4, e00151-19 (2019).

pubmed: 31186311 pmcid: 6584881 doi: 10.1128/mSystems.00151-19

Lipinski, C. A., Lombardo, F., Dominy, B. W. & Feeney, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 23, 3–25 (1997). This study presents, for the first time, ‘the rule of five’, defining five key physiochemical parameters for orally active drugs.

doi: 10.1016/S0169-409X(96)00423-1

Lipinski, C. A. Rule of five in 2015 and beyond: Target and ligand structural limitations, ligand chemistry structure and drug discovery project decisions. Adv. Drug Deliv. Rev. 101, 34–41 (2016).

pubmed: 27154268 doi: 10.1016/j.addr.2016.04.029

Benet, L. Z., Hosey, C. M., Ursu, O. & Oprea, T. I. BDDCS, the Rule of 5 and drugability. Adv. Drug Deliv. Rev. 101, 89–98 (2016).

pubmed: 27182629 pmcid: 4910824 doi: 10.1016/j.addr.2016.05.007

DeGoey, D. A., Chen, H.-J., Cox, P. B. & Wendt, M. D. Beyond the rule of 5: lessons learned from AbbVie’s drugs and compound collection. J. Med. Chem. 61, 2636–2651 (2018).

pubmed: 28926247 doi: 10.1021/acs.jmedchem.7b00717

Doak, B. C., Over, B., Giordanetto, F. & Kihlberg, J. Oral druggable space beyond the rule of 5: insights from drugs and clinical candidates. Chem. Biol. 21, 1115–1142 (2014).

pubmed: 25237858 doi: 10.1016/j.chembiol.2014.08.013

Tyagi, M., Begnini, F., Poongavanam, V., Doak, B. C. & Kihlberg, J. Drug syntheses beyond the rule of 5. Chem. Eur. J. 26, 49–88 (2020).

pubmed: 31483909 doi: 10.1002/chem.201902716

Wright, P. M., Seiple, I. B. & Myers, A. G. The evolving role of chemical synthesis in antibacterial drug discovery. Angew. Chem. Int. Ed. 53, 8840–8869 (2014).

doi: 10.1002/anie.201310843

Agarwal, V. et al. Enzymatic halogenation and dehalogenation reactions: pervasive and mechanistically diverse. Chem. Rev. 117, 5619–5674 (2017).

pubmed: 28106994 pmcid: 5575885 doi: 10.1021/acs.chemrev.6b00571

Wilcken, R., Zimmermann, M. O., Lange, A., Joerger, A. C. & Boeckler, F. M. Principles and applications of halogen bonding in medicinal chemistry and chemical biology. J. Med. Chem. 56, 1363–1388 (2013).

pubmed: 23145854 doi: 10.1021/jm3012068

Convention on Biological Diversity United Nations. Nagoya Protocol on access to genetic resources and the fair and equitable sharing of benefits arising from their utilization to the Convention on Biological Diversity. (Convention on Biological Diversity, 2011) https://www.cbd.int/abs/doc/protocol/nagoya-protocol-en.pdf

Sorokina, M. & Steinbeck, C. Review on natural products databases: where to find data in 2020. J. Cheminform. 12, 20 (2020).

pubmed: 33431011 pmcid: 7118820 doi: 10.1186/s13321-020-00424-9

European Commission. Manifesto for EU COVID-19 research: maximising the accessibility of research results in the fight against COVID-19. (European Commission, 2020) https://ec.europa.eu/info/research-and-innovation/research-area/health-research-and-innovation/coronavirus-research-and-innovation/covid-research-manifesto_en

Wibberg, D. et al. High quality genome sequences of thirteen Hypoxylaceae (Ascomycota) strengthen the phylogenetic family backbone and enable the discovery of new taxa. Fungal Divers. 106, 7–28 (2021).

doi: 10.1007/s13225-020-00447-5

Kling, A. et al. Antibiotics. targeting DnaN for tuberculosis therapy using novel griselimycins. Science 348, 1106–1112 (2015). This study presents a primary example of discovering a new mode of action by self-resistant target identification.

pubmed: 26045430 doi: 10.1126/science.aaa4690

Johnston, C. W. et al. Assembly and clustering of natural antibiotics guides target identification. Nat. Chem. Biol. 12, 233–239 (2016).

pubmed: 26829473 doi: 10.1038/nchembio.2018

Panter, F., Krug, D., Baumann, S. & Müller, R. Self-resistance guided genome mining uncovers new topoisomerase inhibitors from myxobacteria. Chem. Sci. 9, 4898–4908 (2018).

pubmed: 29910943 pmcid: 5982219 doi: 10.1039/C8SC01325J

Mungan, M. D. et al. ARTS 2.0: feature updates and expansion of the Antibiotic Resistant Target Seeker for comparative genome mining. Nucleic Acids Res. 48, W546–W552 (2020). This study presents the update and expansion of the Antibiotic Resistant Target Seeker (ARTS).

pubmed: 32427317 pmcid: 7319560 doi: 10.1093/nar/gkaa374

Emmert-Streib, F., Yang, Z., Feng, H., Tripathi, S. & Dehmer, M. An introductory review of deep learning for prediction models with big data. Front. Artif. Intell. 3, 4 (2020). Comprehensive overview of deep learning models and future developments in artificial intelligence.

pubmed: 33733124 pmcid: 7861305 doi: 10.3389/frai.2020.00004

Schneider, P. et al. Rethinking drug design in the artificial intelligence era. Nat. Rev. Drug. Discov. 19, 353–364 (2020).

pubmed: 31801986 doi: 10.1038/s41573-019-0050-3

Grein, F. et al. Ca

pubmed: 32193379 pmcid: 7081307 doi: 10.1038/s41467-020-15257-1

Cardona, S. T., Selin, C. & Gislason, A. S. Genomic tools to profile antibiotic mode of action. Crit. Rev. Microbiol. 41, 465–472 (2015).

pubmed: 24617440 doi: 10.3109/1040841X.2013.866073

van Camp, P.-J., Haslam, D. B. & Porollo, A. Bioinformatics approaches to the understanding of molecular mechanisms in antimicrobial resistance. Int. J. Mol. Sci. 21, 1363 (2020).

pmcid: 7072858 doi: 10.3390/ijms21041363

O’Rourke, A. et al. Mechanism-of-action classification of antibiotics by global transcriptome profiling. Antimicrob. Agents Chemother. 64, e01207–e01219 (2020).

pubmed: 31907190 pmcid: 7038283 doi: 10.1128/AAC.01207-19

Nonejuie, P., Burkart, M., Pogliano, K. & Pogliano, J. Bacterial cytological profiling rapidly identifies the cellular pathways targeted by antibacterial molecules. Proc. Natl Acad. Sci. USA 110, 16169–16174 (2013).

pubmed: 24046367 pmcid: 3791758 doi: 10.1073/pnas.1311066110

Lamsa, A. et al. Rapid inhibition profiling in Bacillus subtilis to identify the mechanism of action of new antimicrobials. ACS Chem. Biol. 11, 2222–2231 (2016).

pubmed: 27193499 pmcid: 5459310 doi: 10.1021/acschembio.5b01050

Ribeiro da Cunha, B., Fonseca, L. P. & Calado, C. R. C. Metabolic fingerprinting with fourier-transform infrared (FTIR) spectroscopy: towards a high-throughput screening assay for antibiotic discovery and mechanism-of-action elucidation. Metabolites 10, 145 (2020).

pmcid: 7240953 doi: 10.3390/metabo10040145

Eustice, D. C., Feldman, P. A. & Slee, A. M. The mechanism of action of DuP 721, a new antibacterial agent: effects on macromolecular synthesis. Biochem. Biophys. Res. Commun. 150, 965–971 (1988).

pubmed: 2449210 doi: 10.1016/0006-291X(88)90723-1

Sugimoto, A., Maeda, A., Itto, K. & Arimoto, H. Deciphering the mode of action of cell wall-inhibiting antibiotics using metabolic labeling of growing peptidoglycan in Streptococcus pyogenes. Sci. Rep. 7, 1129 (2017).

pubmed: 28442740 pmcid: 5430839 doi: 10.1038/s41598-017-01267-5

Cacace, E., Kritikos, G. & Typas, A. Chemical genetics in drug discovery. Curr. Opin. Syst. Biol. 4, 35–42 (2017).

pubmed: 32715163 pmcid: 7371212 doi: 10.1016/j.coisb.2017.05.020

Santiago, M. et al. Genome-wide mutant profiling predicts the mechanism of a Lipid II binding antibiotic. Nat. Chem. Biol. 14, 601–608 (2018). This study demonstrates how machine learning approaches can be used to predict the mode of action of antibiotics via mutant fitness profiles.

pubmed: 29662210 pmcid: 5964011 doi: 10.1038/s41589-018-0041-4

Wright, M. H. & Sieber, S. A. Chemical proteomics approaches for identifying the cellular targets of natural products. Nat. Prod. Rep. 33, 681–708 (2016).

pubmed: 27098809 pmcid: 5063044 doi: 10.1039/C6NP00001K

Drewes, G. & Knapp, S. Chemoproteomics and chemical probes for target discovery. Trends Biotechnol. 36, 1275–1286 (2018).

pubmed: 30017093 doi: 10.1016/j.tibtech.2018.06.008

Hoerr, V. et al. Characterization and prediction of the mechanism of action of antibiotics through NMR metabolomics. BMC Microbiol. 16, 82 (2016).

pubmed: 27159970 pmcid: 4862084 doi: 10.1186/s12866-016-0696-5

Medeiros-Silva, J. et al. High-resolution NMR studies of antibiotics in cellular membranes. Nat. Commun. 9, 3963 (2018).

pubmed: 30262913 pmcid: 6160437 doi: 10.1038/s41467-018-06314-x

Tietze, L. F., Krewer, B., Major, F. & Schuberth, I. CD-spectroscopy as a powerful tool for investigating the mode of action of unmodified drugs in live cells. J. Am. Chem. Soc. 131, 13031–13036 (2009).

pubmed: 19697908 doi: 10.1021/ja902767f

Altharawi, A., Rahman, K. M. & Chan, K. L. A. Towards identifying the mode of action of drugs using live-cell FTIR spectroscopy. Analyst 144, 2725–2735 (2019).

pubmed: 30865733 doi: 10.1039/C8AN02218F

Cirnski, K., Coetzee, J., Herrmann, J. & Müller, R. Metabolic profiling to determine bactericidal or bacteriostatic effects of new natural products using isothermal microcalorimetry. J. Vis. Exp. 164, e61703 (2020).

Arrowsmith, C. H. et al. The promise and peril of chemical probes. Nat. Chem. Biol. 11, 536–541 (2015).

pubmed: 26196764 pmcid: 4706458 doi: 10.1038/nchembio.1867

Wang, Y. et al. Evidence-based and quantitative prioritization of tool compounds in phenotypic drug discovery. Cell Chem. Biol. 23, 862–874 (2016).

pubmed: 27427232 doi: 10.1016/j.chembiol.2016.05.016

Franken, H. et al. Thermal proteome profiling for unbiased identification of direct and indirect drug targets using multiplexed quantitative mass spectrometry. Nat. Protoc. 10, 1567–1593 (2015).

pubmed: 26379230 doi: 10.1038/nprot.2015.101

Schopper, S. et al. Measuring protein structural changes on a proteome-wide scale using limited proteolysis-coupled mass spectrometry. Nat. Protoc. 12, 2391–2410 (2017).

pubmed: 29072706 doi: 10.1038/nprot.2017.100

Piazza, I. et al. A map of protein-metabolite interactions reveals principles of chemical communication. Cell 172, 358–372 (2018).

pubmed: 29307493 doi: 10.1016/j.cell.2017.12.006

Dai, L. et al. Horizontal cell biology: monitoring global changes of protein interaction states with the proteome-wide cellular thermal shift assay (CETSA). Ann. Rev. Biochem. 88, 383–408 (2019).

pubmed: 30939043 doi: 10.1146/annurev-biochem-062917-012837

Bagherian, M. et al. Machine learning approaches and databases for prediction of drug–target interaction: a survey paper. Brief. Bioinform. 22, 247–269 (2021).

pubmed: 31950972 doi: 10.1093/bib/bbz157

Pliakos, K. & Vens, C. Drug-target interaction prediction with tree-ensemble learning and output space reconstruction. BMC Bioinform. 21, 49 (2020).

doi: 10.1186/s12859-020-3379-z

Davin-Regli, A. et al. Membrane permeability and regulation of drug “influx and efflux” in enterobacterial pathogens. Curr. Drug Targets 9, 750–759 (2008).

pubmed: 18781921 doi: 10.2174/138945008785747824

Louw, G. E. et al. A balancing act: efflux/influx in mycobacterial drug resistance. Antimicrob. Agents Chemother. 53, 3181–3189 (2009).

pubmed: 19451293 pmcid: 2715638 doi: 10.1128/AAC.01577-08

Chitsaz, M. & Brown, M. H. The role played by drug efflux pumps in bacterial multidrug resistance. Essays Biochem. 61, 127–139 (2017).

pubmed: 28258236 doi: 10.1042/EBC20160064

Weston, N., Sharma, P., Ricci, V. & Piddock, L. J. V. Regulation of the AcrAB-TolC efflux pump in Enterobacteriaceae. Res. Microbiol. 169, 425–431 (2018).

pubmed: 29128373 doi: 10.1016/j.resmic.2017.10.005

Ropponen, H.-K., Richter, R., Hirsch, A. K. H. & Lehr, C.-M. Mastering the Gram-negative bacterial barrier – Chemical approaches to increase bacterial bioavailability of antibiotics. Adv. Drug Deliv. Rev. 172, 339–360 (2021).

pubmed: 33705882 doi: 10.1016/j.addr.2021.02.014

Richter, M. F. et al. Predictive compound accumulation rules yield a broad-spectrum antibiotic. Nature 545, 299–304 (2017). This study highlights which physicochemical properties enforce the accumulation of small molecules in Gram-negative bacteria.

pubmed: 28489819 pmcid: 5737020 doi: 10.1038/nature22308

Jukic˅, M., Gobec, S. & Sova, M. Reaching toward underexplored targets in antibacterial drug design. Drug Dev. Res. 80, 6–10 (2019).

pubmed: 30312991 doi: 10.1002/ddr.21465

Manchester, J. I., Buurman, E. T., Bisacchi, G. S. & McLaughlin, R. E. Molecular determinants of AcrB-mediated bacterial efflux implications for drug discovery. J. Med. Chem. 55, 2532–2537 (2012).

pubmed: 22224562 doi: 10.1021/jm201275d

Hevener, K. E. et al. Chapter Eighteen-Special challenges to the rational design of antibacterial agents. Ann. Rep. Med. Chem. 48, 283–298 (2013).

Zavascki, A. P., Goldani, L. Z., Li, J. & Nation, R. L. Polymyxin B for the treatment of multidrug-resistant pathogens: a critical review. J. Antimicrob. Chemother. 60, 1206–1215 (2007).

pubmed: 17878146 doi: 10.1093/jac/dkm357

Ferrer-Espada, R. et al. A permeability-increasing drug synergizes with bacterial efflux pump inhibitors and restores susceptibility to antibiotics in multi-drug resistant Pseudomonas aeruginosa strains. Sci. Rep. 9, 3452 (2019).

pubmed: 30837499 pmcid: 6401119 doi: 10.1038/s41598-019-39659-4

Schweizer, H. P. Understanding efflux in Gram-negative bacteria: opportunities for drug discovery. Exp. Opin. Drug Discov. 7, 633–642 (2012).

doi: 10.1517/17460441.2012.688949

Wagner, S. et al. Novel strategies for the treatment of Pseudomonas aeruginosa infections. J. Med. Chem. 59, 5929–5969 (2016).

pubmed: 26804741 doi: 10.1021/acs.jmedchem.5b01698

Zhang, W., Bai, Y., Wang, Y. & Xiao, W. Polypharmacology in drug discovery: a review from systems pharmacology perspective. Curr. Pharm. Des. 22, 3171–3181 (2016).

pubmed: 26907941 doi: 10.2174/1381612822666160224142812

Proschak, E., Stark, H. & Merk, D. Polypharmacology by design: a medicinal chemist’s perspective on multitargeting compounds. J. Med. Chem. 62, 420–444 (2019).

pubmed: 30035545 doi: 10.1021/acs.jmedchem.8b00760

Cunningham, M. L., Kwan, B. P., Nelson, K. J., Bensen, D. C. & Shaw, K. J. Distinguishing on-target versus off-target activity in early antibacterial drug discovery using a macromolecular synthesis assay. J. Biomol. Screen. 18, 1018–1026 (2013).

pubmed: 23686103 doi: 10.1177/1087057113487208

Singh, R., Sripada, L. & Singh, R. Side effects of antibiotics during bacterial infection: mitochondria, the main target in host cell. Mitochondrion 16, 50–54 (2014).

pubmed: 24246912 doi: 10.1016/j.mito.2013.10.005

Young, M. J. Off-target effects of drugs that disrupt human mitochondrial DNA maintenance. Front. Mol. Biosci. 4, 74 (2017).

pubmed: 29214156 pmcid: 5702650 doi: 10.3389/fmolb.2017.00074

Moullan, N. et al. Tetracyclines disturb mitochondrial function across eukaryotic models: a call for caution in biomedical research. Cell Rep. 10, 1681–1691 (2015).

pubmed: 25772356 pmcid: 4565776 doi: 10.1016/j.celrep.2015.02.034

Pasternak, B., Inghammar, M. & Svanström, H. Fluoroquinolone use and risk of aortic aneurysm and dissection: nationwide cohort study. BMJ 360, k678 (2018).

pubmed: 29519881 pmcid: 5842359 doi: 10.1136/bmj.k678

Fief, C. A., Hoang, K. G., Phipps, S. D., Wallace, J. L. & Deweese, J. E. Examining the impact of antimicrobial fluoroquinolones on human DNA topoisomerase IIα and IIβ. ACS Omega 4, 4049–4055 (2019).

pubmed: 31459613 pmcid: 6648947 doi: 10.1021/acsomega.8b03428

Becattini, S., Taur, Y. & Pamer, E. G. Antibiotic-induced changes in the intestinal microbiota and disease. Trends Mol. Med. 22, 458–478 (2016).

pubmed: 27178527 pmcid: 4885777 doi: 10.1016/j.molmed.2016.04.003

Bhalodi, A. A., van Engelen, T. S. R., Virk, H. S. & Wiersinga, W. J. Impact of antimicrobial therapy on the gut microbiome. J. Antimicrob. Chemother. 74, i6–i15 (2019).

pubmed: 30690540 pmcid: 6382031 doi: 10.1093/jac/dky530

Wipperman, M. F. et al. Antibiotic treatment for Tuberculosis induces a profound dysbiosis of the microbiome that persists long after therapy is completed. Sci. Rep. 7, 10767 (2017).

pubmed: 28883399 pmcid: 5589918 doi: 10.1038/s41598-017-10346-6

Xu, L. et al. The effect of antibiotics on the gut microbiome: a metagenomics analysis of microbial shift and gut antibiotic resistance in antibiotic treated mice. BMC Genomics 21, 263 (2020).

pubmed: 32228448 pmcid: 7106814 doi: 10.1186/s12864-020-6665-2

Evans, L. E. et al. Exploitation of antibiotic resistance as a novel drug target: development of a β-lactamase-activated antibacterial prodrug. J. Med. Chem. 62, 4411–4425 (2019).

pubmed: 31009558 pmcid: 6511942 doi: 10.1021/acs.jmedchem.8b01923

Hong, J. Natural product synthesis at the interface of chemistry and biology. Chem. Eur. J. 20, 10204–10212 (2014).

pubmed: 25043880 doi: 10.1002/chem.201402804

Bauer, A. & Brönstrup, M. Industrial natural product chemistry for drug discovery and development. Nat. Prod. Rep. 31, 35–60 (2014).

pubmed: 24142193 doi: 10.1039/C3NP70058E

Sucipto, H., Pogorevc, D., Luxenburger, E., Wenzel, S. C. & Müller, R. Heterologous production of myxobacterial α-pyrone antibiotics in Myxococcus xanthus. Metab. Eng. 44, 160–170 (2017).

pubmed: 29030273 doi: 10.1016/j.ymben.2017.10.004

Pogorevc, D. et al. Production optimization and biosynthesis revision of corallopyronin A, a potent anti-filarial antibiotic. Metab. Eng. 55, 201–211 (2019).

pubmed: 31340171 doi: 10.1016/j.ymben.2019.07.010

Sun, C. et al. A robust platform for the synthesis of new tetracycline antibiotics. J. Am. Chem. Soc. 130, 17913–17927 (2008).

pubmed: 19053822 pmcid: 2681267 doi: 10.1021/ja806629e

Hogan, P. C. et al. Large-scale preparation of key building blocks for the manufacture of fully synthetic macrolide antibiotics. J. Antibiot. 71, 318–325 (2018).

doi: 10.1038/ja.2017.116

Hüttel, S. et al. Discovery and total synthesis of natural cystobactamid derivatives with superior activity against Gram-negative pathogens. Angew. Chem. Int. Ed. 56, 12760–12764 (2017).

doi: 10.1002/anie.201705913

Zong, Y. et al. Gram-scale total synthesis of teixobactin promoting binding mode study and discovery of more potent antibiotics. Nat. Commun. 10, 3268 (2019).

pubmed: 31332172 pmcid: 6646333 doi: 10.1038/s41467-019-11211-y

Crater, J. S. & Lievense, J. C. Scale-up of industrial microbial processes. FEMS Microbiol. Lett. 365, fny138 (2018).

pmcid: 5995164 doi: 10.1093/femsle/fny138

Nielsen, J. et al. (eds) Metabolic Engineering. Advances in Biochemical Engineering/Biotechnology Vol 73 (Springer, 2001).

Pham, J. V. et al. A review of the microbial production of bioactive natural products and biologics. Front. Microbiol. 10, 1404 (2019).

pubmed: 31281299 pmcid: 6596283 doi: 10.3389/fmicb.2019.01404

Balani, S. K., Miwa, G. T., Gan, L.-S., Wu, J.-T. & Lee, F. W. Strategy of utilizing in vitro and in vivo ADME tools for lead optimization and drug candidate selection. Curr. Top. Med. Chem. 5, 1033–1038 (2005).

pubmed: 16181128 doi: 10.2174/156802605774297038

Chung, T. D. Y., Terry, D. B. & Smith, L. H. in Assay Guidance Manual (eds Markossian, S. et al.) (Eli Lilly & Company and the National Center for Advancing Translational Sciences, 2015).

Reichel, A. & Lienau, P. Pharmacokinetics in drug discovery: an exposure-centred approach to optimising and predicting drug efficacy and safety. Handb. Exp. Pharmacol. 232, 235–260 (2016). This article highlights the central role of pharmacokinetics in drug discovery.

pubmed: 26330260 doi: 10.1007/164_2015_26

Singh, S. S. Preclinical pharmacokinetics: an approach towards safer and efficacious drugs. Curr. Drug Metab. 7, 165–182 (2006).

pubmed: 16472106 doi: 10.2174/138920006775541552

Shi, J. & Zha, W. Predicting human pharmacokinetics: physiologically based pharmacokinetic modeling and in silico ADME prediction in early drug discovery. Eur. J. Drug. Metab. Pharmacokinet. 44, 135–137 (2019).

pubmed: 30136219 doi: 10.1007/s13318-018-0503-9

Xiong, G. et al. ADMETlab 2.0: an integrated online platform for accurate and comprehensive predictions of ADMET properties. Nucleic Acids Res. 49, W5–W14 (2021). Redesigned version of the widely used ADMETlab web server for predictions of pharmacokinetics and toxicity properties of chemicals.

pubmed: 33893803 pmcid: 8262709 doi: 10.1093/nar/gkab255

Krause, K. M. et al. Potent LpxC inhibitors with in vitro activity against multidrug-resistant Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 63, e00977-19 (2019).

pubmed: 31451507 pmcid: 6811409 doi: 10.1128/AAC.00977-19

Cohen, F. et al. Optimization of LpxC inhibitors for antibacterial activity and cardiovascular safety. ChemMedChem 14, 1560–1572 (2019).

pubmed: 31283109 doi: 10.1002/cmdc.201900287

Felmlee, M. A., Morris, M. E. & Mager, D. E. Mechanism-based pharmacodynamic modeling. Meth. Mol. Biol. 929, 583–600 (2012).

doi: 10.1007/978-1-62703-050-2_21

Lepak, A. J. & Andes, D. R. in Antibiotic Pharmacodynamics Vol. 191 (eds Rotschafer, J. C., Andes, D. R. & Rodvold, K. A.) 59–87 (Springer, 2016).

van Peer, A., Snoeck, E., Huang, M. L. & Heykants, J. Pharmacokinetic-pharmacodynamic relationships in phase I/phase II of drug development. Eur. J. Drug Metab. Pharmacokinet. 18, 49–59 (1993).

pubmed: 8335039 doi: 10.1007/BF03220008

Zhao, M., Lepak, A. J. & Andes, D. R. Animal models in the pharmacokinetic/pharmacodynamic evaluation of antimicrobial agents. Bioorg. Med. Chem. 24, 6390–6400 (2016).

pubmed: 27887963 doi: 10.1016/j.bmc.2016.11.008

McGinnity, D. F., Collington, J., Austin, R. P. & Riley, R. J. Evaluation of human pharmacokinetics, therapeutic dose and exposure predictions using marketed oral drugs. Curr. Drug Metab. 8, 463–479 (2007).

pubmed: 17584017 doi: 10.2174/138920007780866799

Zou, P. et al. Applications of human pharmacokinetic prediction in first-in-human dose estimation. AAPS J. 14, 262–281 (2012).

pubmed: 22407287 pmcid: 3326168 doi: 10.1208/s12248-012-9332-y

Page, K. M. Validation of early human dose prediction: a key metric for compound progression in drug discovery. Mol. Pharmaceutics 13, 609–620 (2016).

doi: 10.1021/acs.molpharmaceut.5b00840

Maher, S., Brayden, D. J., Casettari, L. & Illum, L. Application of permeation enhancers in oral delivery of macromolecules: an update. Pharmaceutics 11, 41 (2019).

pmcid: 6359609 doi: 10.3390/pharmaceutics11010041

Ma, X. & Williams, R. O. Polymeric nanomedicines for poorly soluble drugs in oral delivery systems: an update. J. Pharm. Invest. 48, 61–75 (2018).

Pridgen, E. M., Alexis, F. & Farokhzad, O. C. Polymeric nanoparticle technologies for oral drug delivery. Clin. Gastroenterol. Hepatol. 12, 1605–1610 (2014).

pubmed: 24981782 pmcid: 4171204 doi: 10.1016/j.cgh.2014.06.018

Bassetti, M., Vena, A., Russo, A. & Peghin, M. Inhaled liposomal antimicrobial delivery in lung infections. Drugs 80, 1309–1318 (2020).

pubmed: 32691293 pmcid: 7479014 doi: 10.1007/s40265-020-01359-z

Bulbake, U., Doppalapudi, S., Kommineni, N. & Khan, W. Liposomal formulations in clinical use: an updated review. Pharmaceutics 9, 12 (2017).

pmcid: 5489929 doi: 10.3390/pharmaceutics9020012

Russell, W. M. S. & Burch, R. L. The Principles of Humane Experimental Technique (Methuen & Co. Limited, 1959). This work defines, for the first time, the 3Rs principle as the present ethical standard in animal research.

Jaeger, A., Sauder, P., Kopferschmitt & Dahlet, M. Toxicokinetics in clinical toxicology. Acta Clin. Belg. 45, 1–12 (1990).

doi: 10.1080/17843286.1990.11718122

Goehl, T. J. Toxicokinetics in the national toxicology program. NIDA Res. Monogr. 173, 273–304 (1997).

pubmed: 9260193

Low, Y. S., Sedykh, A. Y., Rusyn, I. & Tropsha, A. Integrative approaches for predicting in vivo effects of chemicals from their structural descriptors and the results of short-term biological assays. Curr. Top. Med. Chem. 14, 1356–1364 (2014).

pubmed: 24805064 pmcid: 5344042 doi: 10.2174/1568026614666140506121116

Cox, L. A. T., Popken, D. A., Kaplan, A. M., Plunkett, L. M. & Becker, R. A. How well can in vitro data predict in vivo effects of chemicals? Rodent carcinogenicity as a case study. Regul. Toxicol. Pharmacol. 77, 54–64 (2016).

doi: 10.1016/j.yrtph.2016.02.005

Zhang, X. et al. Zebrafish and Galleria mellonella: Models to identify the subsequent infection and evaluate the immunological differences in different Klebsiella pneumoniae intestinal colonization strains. Front. Microbiol. 10, 2750 (2019).

pubmed: 31849893 pmcid: 6900958 doi: 10.3389/fmicb.2019.02750

Herlich, J. A. et al. The non-GLP toleration/dose range finding study: design and methodology used in an early toxicology screening program. Proc. West. Pharmacol. Soc. 52, 94–98 (2009).

pubmed: 22128433

Alirol, E. et al. Multidrug-resistant gonorrhea: A research and development roadmap to discover new medicines. PLoS Med. 14, e1002366 (2017).

pubmed: 28746372 pmcid: 5528252 doi: 10.1371/journal.pmed.1002366

BEAM Alliance. Position Paper 2017: Key Guidelines to implement effective measures toward SMEs to revive the antibacterial R&D field. (BEAM Alliance, 2017) https://beam-alliance.eu/wp-content/uploads/2019/03/2017-11-16-beam-alliance-position-paper.pdf

BEAM Alliance. A new vision for AMR innovation to support medical care. (BEAM Alliance, 2019) https://beam-alliance.eu/wp-content/uploads/2019/10/beam-alliance-a-new-vision-to-support-amr-innovation.pdf

BEAM Alliance. Reflexion paper on the EU pharmaceutical strategy roadmap. (BEAM Alliance, 2020) https://beam-alliance.eu/wp-content/uploads/2020/07/roadmap-reflexion-paper.pdf

ReAct Europe. AMR stakeholder mapping. (ReAct, 2016) https://www.reactgroup.org/uploads/Stakeholder%20Analysis_ReActForWHO.pdf

Fisher, J. F. & Mobashery, S. Endless resistance. Endless antibiotics? MedChemComm 7, 37–49 (2016).

pubmed: 27746889 doi: 10.1039/C5MD00394F

DiMasi, J. A., Grabowski, H. G. & Hansen, R. W. Innovation in the pharmaceutical industry: New estimates of R&D costs. J. Health Econ. 47, 20–33 (2016).

pubmed: 26928437 doi: 10.1016/j.jhealeco.2016.01.012

The Boston Consulting Group. Breaking through the wall – A call for concerted action on antibiotics research and development. (Bundesministerium für Gesundheit, 2017) https://www.bundesgesundheitsministerium.de/fileadmin/Dateien/5_Publikationen/Gesundheit/Berichte/GUARD_Follow_Up_Report_Full_Report_final.pdf

Access to Medicine Foundation. Antimicrobial resistance benchmark 2018. (Access to Medicine Foundation, 2018) https://accesstomedicinefoundation.org/media/uploads/downloads/5f292e3996b58_Antimicrobial-Resistance-Benchmark-2018.pdf

Paul, S. M. et al. How to improve R&D productivity: the pharmaceutical industry’s grand challenge. Nat. Rev. Drug Discov. 9, 203–214 (2010).

pubmed: 20168317 doi: 10.1038/nrd3078

Pieroni, M., Wan, B., Cho, S., Franzblau, S. G. & Costantino, G. Design, synthesis and investigation on the structure–activity relationships of N-substituted 2-aminothiazole derivatives as antitubercular agents. Eur. J. Med. Chem. 72, 26–34 (2014).

pubmed: 24333612 doi: 10.1016/j.ejmech.2013.11.007

Azzali, E. et al. Substituted N-phenyl-5-(2-(phenylamino)thiazol-4-yl)isoxazole-3-carboxamides are valuable antitubercular candidates that evade innate efflux machinery. J. Med. Chem. 60, 7108–7122 (2017).

pubmed: 28749666 doi: 10.1021/acs.jmedchem.7b00793

Bohacek, R. S., McMartin, C. & Guida, W. C. The art and practice of structure-based drug design: a molecular modeling perspective. Med. Res. Rev. 16, 3–50 (1996).

pubmed: 8788213 doi: 10.1002/(SICI)1098-1128(199601)16:1<3::AID-MED1>3.0.CO;2-6

Hartwig, J. F. Evolution of a fourth generation catalyst for the amination and thioetherification of aryl halides. Acc. Chem. Res. 41, 1534–1544 (2008).

pubmed: 18681463 pmcid: 2819174 doi: 10.1021/ar800098p

Abdel-Magid, A. F. & Mehrman, S. J. A review on the use of sodium triacetoxyborohydride in the reductive amination of ketones and aldehydes. Org. Process. Res. Dev. 10, 971–1031 (2006).

doi: 10.1021/op0601013

Gedeck, P. et al. Benefit of retraining pK

pubmed: 26052622 doi: 10.1021/acs.jcim.5b00172

Lovering, F., Bikker, J. & Humblet, C. Escape from flatland: increasing saturation as an approach to improving clinical success. J. Med. Chem. 52, 6752–6756 (2009).

pubmed: 19827778 doi: 10.1021/jm901241e

Zender, M. et al. Discovery and biophysical characterization of 2-amino-oxadiazoles as novel antagonists of PqsR, an important regulator of Pseudomonas aeruginosa virulence. J. Med. Chem. 56, 6761–6774 (2013).

pubmed: 23919758 doi: 10.1021/jm400830r

Zender, M. et al. Flexible fragment growing boosts potency of quorum-sensing inhibitors against Pseudomonas aeruginosa virulence. ChemMedChem 15, 188–194 (2020).

pubmed: 31709767 doi: 10.1002/cmdc.201900621

Ahmed, A. S. A. et al. PqsR inverse agonists. Patent WO2020007938A1 (2020).

Schütz, C. et al. A new PqsR inverse agonist potentiates tobramycin efficacy to eradicate Pseudomonas aeruginosa biofilms. Adv. Sci. 8, 2004369 (2021). Demonstrates the synergistic effect of a quorum sensing-targeting pathoblocker with a standard-of-care antibiotic in a Pseudomonas aeruginosa lung infection mouse model.

doi: 10.1002/advs.202004369

Oliver, T. J. & Sinclair, A. C. Antibiotic M-319. US Patent US3155582A (1964).

Mitscher, L. A. et al. Structure of chelocardin, a novel tetracycline antibiotic. J. Am. Chem. Soc. 92, 6070–6071 (1970).

pubmed: 5459200 doi: 10.1021/ja00723a049

Petkovic, H., Raspor, P. & Lesnik, U. Genes for biosynthesis of tetracycline compounds and uses thereof. US Patent US8361777B2 (2013).

Lukežic˅, T. et al. Identification of the chelocardin biosynthetic gene cluster from Amycolatopsis sulphurea: a platform for producing novel tetracycline antibiotics. Microbiology 159, 2524–2532 (2013).

pubmed: 24043447 doi: 10.1099/mic.0.070995-0

Molnar, V., Matković, Z., Tambić, T. & Kozma, C. Klinicko-farmakolosko ispitivanje kelokardina u bolesnika s infekcijom mokraćnih putova. Lijec. Vjesn. 99, 560–562 (1977).

pubmed: 339024

Lukežic˅, T. et al. Engineering atypical tetracycline formation in Amycolatopsis sulphurea for the production of modified chelocardin antibiotics. ACS Chem. Biol. 14, 468–477 (2019).

pubmed: 30747520 doi: 10.1021/acschembio.8b01125

Flores-Mireles, A. L., Walker, J. N., Caparon, M. & Hultgren, S. J. Urinary tract infections: epidemiology, mechanisms of infection and treatment options. Nat. Rev. Microbiol. 13, 269–284 (2015).

pubmed: 25853778 pmcid: 4457377 doi: 10.1038/nrmicro3432

Irschik, H., Jansen, R., Höfle, G., Gerth, K. & Reichenbach, H. The corallopyronins, new inhibitors of bacterial RNA synthesis from Myxobacteria. J. Antibiot. 38, 145–152 (1985).

doi: 10.7164/antibiotics.38.145

O’Neill, A. et al. RNA polymerase inhibitors with activity against rifampin-resistant mutants of Staphylococcus aureus. Antimicrob. Agents Chemother. 44, 3163–3166 (2000).

pubmed: 11036042 pmcid: 101622 doi: 10.1128/AAC.44.11.3163-3166.2000

Belogurov, G. A. et al. Transcription inactivation through local refolding of the RNA polymerase structure. Nature 457, 332–335 (2008).

pubmed: 18946472 pmcid: 2628454 doi: 10.1038/nature07510

Schäberle, T. F. et al. Insights into structure–activity relationships of bacterial RNA polymerase inhibiting corallopyronin derivatives. J. Nat. Prod. 78, 2505–2509 (2015).

pubmed: 26431157 doi: 10.1021/acs.jnatprod.5b00175

Schiefer, A. et al. Corallopyronin A specifically targets and depletes essential obligate Wolbachia endobacteria from filarial nematodes in vivo. J. Infect. Dis. 206, 249–257 (2012).

pubmed: 22586066 pmcid: 3490692 doi: 10.1093/infdis/jis341

Pfarr, K. M. et al. Compounds for use in the treatment of filariasis. US Patent US9687470B2 (2017).

Pfarr, K. M. et al. Compounds for use in the treatment of filariasis. Patent EP2704708B1 (2017).

Schiefer, A. et al. Corallopyronin A for short-course anti-wolbachial, macrofilaricidal treatment of filarial infections. PLoS Negl. Trop. Dis. 14, e0008930 (2020).

pubmed: 33284808 pmcid: 7746275 doi: 10.1371/journal.pntd.0008930

World Health Organization (WHO). Ending the neglect to attain the Sustainable Development Goals – A road map for neglected tropical diseases 2021–2030 (WHO, 2020) https://www.who.int/neglected_diseases/resources/who-ucn-ntd-2020.01/en/

Loeper, N. et al. Elaborations on Corallopyronin A as a novel treatment strategy against genital chlamydial infections. Front. Microbiol. 10, 943 (2019).

pubmed: 31134007 pmcid: 6514060 doi: 10.3389/fmicb.2019.00943

Kock, F. et al. Orientia tsutsugamushi is highly susceptible to the RNA polymerase switch region inhibitor corallopyronin A in vitro and in vivo. Antimicrob. Agents Chemother. 62, e01732-17 (2018).

pubmed: 29358295 pmcid: 5913972 doi: 10.1128/AAC.01732-17

Shima, K. et al. Effective inhibition of rifampicin-resistant Chlamydia trachomatis by the novel DNA-dependent RNA polymerase inhibitor corallopyronin A. Int. J. Antimicrob. Agents 52, 523–524 (2018).

pubmed: 30092271 doi: 10.1016/j.ijantimicag.2018.07.025

Sucipto, H. et al. Production of myxopyronin and of its derivatives. Patent EP2994535A1 (2018).

Towards the sustainable discovery and development of new antibiotics.

Journal

Informations de publication

Résumé

Identifiants

Types de publication

Langues

Sous-ensembles de citation

Pagination

Informations de copyright

Références

Auteurs

Classifications MeSH